DK0614374T3 - Monoklonalt museantistof (5c8) genkender et menneskeligt glycoprotein på overfladen af T-lymfocytter - Google Patents

Monoklonalt museantistof (5c8) genkender et menneskeligt glycoprotein på overfladen af T-lymfocytter

Info

Publication number
DK0614374T3
DK0614374T3 DK92925316T DK92925316T DK0614374T3 DK 0614374 T3 DK0614374 T3 DK 0614374T3 DK 92925316 T DK92925316 T DK 92925316T DK 92925316 T DK92925316 T DK 92925316T DK 0614374 T3 DK0614374 T3 DK 0614374T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibody
provides
hybridoma
produced
lymphocytes
Prior art date
Application number
DK92925316T
Other languages
English (en)
Other versions
DK0614374T4 (da
Inventor
Seth Lederman
Leonard Chess
Michael J Yellin
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25157875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0614374(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of DK0614374T3 publication Critical patent/DK0614374T3/da
Application granted granted Critical
Publication of DK0614374T4 publication Critical patent/DK0614374T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
DK92925316T 1991-11-15 1992-11-16 Monoklonalt museantistof (5c8) genkender et menneskeligt glycoprotein på overfladen af T-lymfocytter DK0614374T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/792,728 US5474771A (en) 1991-11-15 1991-11-15 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
PCT/US1992/009955 WO1993009812A1 (en) 1991-11-15 1992-11-16 MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES

Publications (2)

Publication Number Publication Date
DK0614374T3 true DK0614374T3 (da) 2003-12-08
DK0614374T4 DK0614374T4 (da) 2008-05-13

Family

ID=25157875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92925316T DK0614374T4 (da) 1991-11-15 1992-11-16 Monoklonalt museantistof (5c8) genkender et menneskeligt glycoprotein på overfladen af T-lymfocytter

Country Status (10)

Country Link
US (11) US5474771A (da)
EP (2) EP0614374B2 (da)
JP (6) JP3447733B2 (da)
AT (1) ATE247166T1 (da)
AU (1) AU675922B2 (da)
CA (2) CA2123224C (da)
DE (1) DE69233163T3 (da)
DK (1) DK0614374T4 (da)
ES (1) ES2207634T5 (da)
WO (1) WO1993009812A1 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DK0679191T3 (da) * 1993-01-22 2004-04-13 Immunex Corp Påvisning og behandling af mutationer i et CD40-ligand-gen
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
DE69422523T2 (de) * 1993-09-02 2000-10-12 Bristol Myers Squibb Pharmaceu Anti-gp39 antikoerper und deren verwendungen
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ES2251719T3 (es) 1994-04-28 2006-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para la proliferacion y diferenciacion de celulas b y su empleo.
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20030099642A1 (en) * 1996-04-22 2003-05-29 Michael J. Yellin Therapeutic applications for the anti-t-bam (cd40l) monoclonal antibody 5c8 in the treatment of vasculitis
WO1997026000A1 (en) * 1996-01-16 1997-07-24 The Trustees Of Columbia Univeristy In The City Of New York Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
EE9900010A (et) * 1996-07-08 1999-06-15 The Trustees Of Columbia University In The City Of New York T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
KR100478322B1 (ko) * 1996-07-08 2005-08-31 바이오겐 아이덱 엠에이 인코포레이티드 평활근세포와관련된질병을치료하기위한t－bam(cd４０l)기법의치료적용도
AU3986697A (en) * 1996-08-19 1998-03-06 Rajko D. Medenica Use of molt4 cd69 expression to determine the presence and activity of interferon inhibitors
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CZ297680B6 (cs) * 1997-01-10 2007-03-07 Biogen, Inc. Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu
EP0966302B1 (en) * 1997-01-10 2007-03-14 Biogen Idec MA Inc. Methods of therapeutic administration of anti-cd40l compounds
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
WO1998052606A1 (en) * 1997-05-17 1998-11-26 Biogen, Inc. Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
EP1005372B1 (en) * 1997-06-20 2002-01-02 Tanox Pharma B.V. Anti-cd40l immunotoxins for the treatment of diseases
EP1754490A3 (en) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
CZ295805B6 (cs) * 1997-06-20 2005-11-16 Biogen Idec Ma Inc. Léčivý přípravek obsahující monoklonální protilátku anti-CD154 nebo její derivát pro léčení syndromu inhibice exogenního proteinu
EE9900588A (et) * 1997-06-20 2000-08-15 Biogen, Incorporated CD154 blokaadravi pankreasesaarte koe transplantatsiooni korral
AU8266798A (en) * 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
ES2251120T3 (es) * 1997-12-17 2006-04-16 Immunex Corporation Glicoproteinas de superficie celular asociadas a los linfomas b humanos-ulbp, adn y polipeptidos.
CN1173735C (zh) * 1998-04-03 2004-11-03 达特茅斯学院理事 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用
WO2000039588A1 (en) * 1998-12-24 2000-07-06 Glaxowellcome B.V. Detection of preactivated phagocytes
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
US7163686B1 (en) * 1999-05-15 2007-01-16 The Regents Of The University Of California Protein A based binding domains with desirable activities
WO2001030386A1 (en) * 1999-10-22 2001-05-03 Biogen, Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
EP1299542A2 (en) * 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
AU8704101A (en) * 2000-09-01 2002-03-13 Biogen Inc Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
AU2001287040A1 (en) * 2000-09-01 2002-03-13 Biogen, Inc. Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
US6753080B1 (en) 2002-01-29 2004-06-22 3M Innovative Properties Company Receptor medium having a microfibrillated surface
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20040006515A1 (en) * 2002-07-03 2004-01-08 Brey Curtis S. Method for supplying framing materials
EP1613775B1 (en) * 2003-03-26 2012-08-29 Multicell Immunotherapeutics, Inc. Selected rna motifs in anti-leukemia therapy
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
CA2528551A1 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
ZA200608126B (en) * 2004-03-01 2008-02-27 Braun Melsungen Ag Hydroxyethyl starch
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20080178489A1 (en) * 2007-01-15 2008-07-31 Roger Dionne Shaver saver
MX2009010120A (es) 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
EP2242512B1 (en) * 2008-01-15 2016-04-27 The Board of Trustees of the Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
DK3912643T3 (da) 2009-02-13 2022-10-17 Immunomedics Inc Immunokonjugater med en intracellulært-spaltelig binding
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
LT2731973T (lt) 2011-07-13 2018-02-26 Ucb Biopharma Sprl Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN118001422A (zh) 2012-12-13 2024-05-10 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN106132436B (zh) 2014-02-21 2021-06-15 Ibc药品公司 通过诱导对trop-2表达细胞的免疫应答的疾病疗法
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2969847A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
KR20180030917A (ko) 2015-08-05 2018-03-26 얀센 바이오테크 인코포레이티드 항-cd154 항체 및 그의 사용 방법
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
WO2021001458A1 (en) 2019-07-01 2021-01-07 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2022205313A1 (en) 2021-01-06 2023-07-20 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340829A (en) 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US5102909A (en) 1988-07-28 1992-04-07 Theracel Corporation Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH04309064A (ja) * 1991-04-05 1992-10-30 Fuji Xerox Co Ltd 画像読取装置
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
DE69233402T3 (de) * 1991-10-25 2009-06-25 Immunex Corp., Seattle Neue cytokine
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
DE69422523T2 (de) 1993-09-02 2000-10-12 Bristol Myers Squibb Pharmaceu Anti-gp39 antikoerper und deren verwendungen
AU7643094A (en) 1993-09-02 1995-03-22 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
EP0966302B1 (en) 1997-01-10 2007-03-14 Biogen Idec MA Inc. Methods of therapeutic administration of anti-cd40l compounds
CZ297680B6 (cs) 1997-01-10 2007-03-07 Biogen, Inc. Farmaceutický prostredek s obsahem protilátek anti-CD40L nebo jejich derivátu
CN1154463C (zh) 1997-01-23 2004-06-23 大正制药株式会社 持效生发剂

Also Published As

Publication number Publication date
JP2004000206A (ja) 2004-01-08
EP0614374A1 (en) 1994-09-14
US6331433B1 (en) 2001-12-18
JPH07505761A (ja) 1995-06-29
DE69233163T3 (de) 2008-11-20
US20030077280A1 (en) 2003-04-24
US6610294B1 (en) 2003-08-26
JP2006034293A (ja) 2006-02-09
US6331615B1 (en) 2001-12-18
JP4037882B2 (ja) 2008-01-23
JP3833958B2 (ja) 2006-10-18
EP1097942A3 (en) 2001-10-31
AU3141993A (en) 1993-06-15
US5993816A (en) 1999-11-30
CA2123224A1 (en) 1993-05-27
US20050037005A1 (en) 2005-02-17
EP0614374B1 (en) 2003-08-13
ATE247166T1 (de) 2003-08-15
JP2003024083A (ja) 2003-01-28
JP2007332150A (ja) 2007-12-27
ES2207634T5 (es) 2008-06-16
DE69233163D1 (de) 2003-09-18
EP1097942A2 (en) 2001-05-09
EP0614374A4 (en) 1995-06-14
JP3447733B2 (ja) 2003-09-16
JP2006034294A (ja) 2006-02-09
US6793924B2 (en) 2004-09-21
AU675922B2 (en) 1997-02-27
EP0614374B2 (en) 2008-03-12
CA2378820A1 (en) 1993-05-27
US6592868B1 (en) 2003-07-15
DE69233163T2 (de) 2004-05-27
CA2123224C (en) 2005-01-25
US5474771A (en) 1995-12-12
JP3889722B2 (ja) 2007-03-07
US6451310B1 (en) 2002-09-17
WO1993009812A1 (en) 1993-05-27
ES2207634T3 (es) 2004-06-01
US6403091B1 (en) 2002-06-11
DK0614374T4 (da) 2008-05-13
US6455044B1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
DK0614374T4 (da) Monoklonalt museantistof (5c8) genkender et menneskeligt glycoprotein på overfladen af T-lymfocytter
EP0184187A3 (en) Mouse-human chimaeric immunoglobulin heavy chain, and chimaeric dna encoding it
NL300005I1 (nl) Chimerische immuunglobulinen met specificiteit voor p55-TAC-eiwit van de IL-2-receptor.
CY1107858T1 (el) Ccr5 αντισωματα pa14
DK0380068T3 (da) Ekspressionssystem til fremstilling af kimære monoklonale antistoffer
AU629135B2 (en) Monoclonal antibody against melanoma
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
ES2114547T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c.
Suzuki et al. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
EP0221561A3 (en) Antigen indicative of human breast cancer and assays based thereon
AU2440188A (en) Immunoassays using antigens produced in heterologous organisms
NO921219D0 (no) Somatostatin reseptor
EP1734054A3 (en) Anti-human thymidylate synthase monoclonal antibody and hybridoma capable of producing the same